Atrial fibrillation (AF) is the most common cardiac arrhythmia encountered in clinical practice. This arrhythmia is responsible for 15% of strokes and more than 30% of strokes on people over 65 years.
According to studies, 30 to 40% of isolated atrial fibrillations could be familial. Atrial fibrillation has significant genetic heterogeneity. About 40 genes have been identified as potentially involved. Studies have identified genes common to the risk of atrial fibrillation and stroke. Despite the pathophysiology of atrial fibrillation has been intensively and extensively studied for almost a century, there are still many questions. The pathophysiology is not sufficiently understood to allow finding more effective therapies. It is necessary to identify genetic determinants and thus potentially new pharmacological targets more adapted.
The establishment of a biological database will test hypotheses concerning the genetic origin and thromboembolic process of atrial fibrillation and associated stroke.
Eligibility
Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Group 1a
* Inclusion Criteria :
\- AF history
* Exclusion Criteria :
* No AF history
* patient who didn't signed consent
Group 1b
* Inclusion Criteria :
* AF history
* Scheduled electrophysiological exploration or AF ablation
* Exclusion Criteria :
* No AF history
* pregnant women
* patient who didn't signed consent
Group 1c
* Inclusion Criteria :
* AF/AT history
* Stroke history
* Exclusion Criteria :
* No Stroke history
* patient who didn't signed consent
Group 2
* Inclusion Criteria :
* patient over 80
* ECG: sinusal rhythm
* TTE : no left atrial dilatation
* Exclusion Criteria :
* atrial fibrillation history
* TTE : Left atria \>25cm², \> 34m/m2), FEVG \< 50%
* ECG : QRS \> 90 ms
* cardiac pathologies (excepted hypertension and valvulopathies)
* History of stroke and transient ischemic attack
* patient who didn't signed consent
Group 3
* Inclusion Criteria :
* cryptogenic stroke or transient ischemic attack history before 50 yo
* No AF history
* Exclusion Criteria :
* AF history
* stroke or transient ischemic attack over 50 yo
* patient who didn't signed consent
Primary outcome measure(s)
Quality of DNA sample — 1 day (the day of the storage) Quality is based on the measure of the purity of DNA with absorbance assay at 260/280nm on a spectrophotometer. For Plasma sample, purity is based on absence of hemolyzed blood by visual observation.
Quality of Plasma sample — 1 day (the day of the storage) Quality is based on the purity of Plasma sample that is based on absence of hemolyzed blood by visual observation.
Quality of preservation of the sample — 7 years (during all the duration of the collection) The quality of preservation of the sample throughout the conservation duration is based on the number of freezing/thawing of each cryotube that will be notified. As weel as any interruption in the freezing process (power failure, freezer failure).
Trial sites (5)
Facility
City
Region
Status
Service neurologie Centre hospitalier Fleyriat
Bourg-en-Bresse
France
Recruiting
Service d'urgences Neurovasculaires - service de neurologie vasculaire , Hôpital Pierre Wertheimer
Bron
France
Recruiting
Service de rythmologie, hôpital cardiologique Louis Pradel
Bron
France
Recruiting
Service de médecine gériatrique Centre hospitalier Lyon Sud, Groupement hospitalier Sud
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.